Work

Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

Year: 2010

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v116.21.3082.3082

Authors: Srdan Verstovsek, H. Joachim Deeg, Olatoyosi Odenike, Joy Zhu, Hagop Kantarjian, Zeev Estrov, Bart Lee Scott, Deborah A Thomas

Institutions: The University of Texas MD Anderson Cancer Center, University of Washington, Fred Hutch Cancer Center, University of Chicago, University of Chicago Medical Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2577901327

FWCI: 4.143

Cites:

Cited by: 37

Related to: 10